NEOK001 for Cancer

This trial tests a new treatment, NEOK001, for certain solid tumors that have spread or cannot be removed. The goal is to determine the optimal dose and evaluate its effectiveness. The trial has two parts: one to identify the safest dose and another to test this dose more broadly. Suitable participants have a type of cancer with no current standard treatment and at least one measurable tumor. As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding its effects in people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that NEOK001 is promising in terms of safety. Studies indicate it has a good safety profile, meaning most patients can handle the treatment well. In trials, NEOK001 was generally well-tolerated, which is a positive sign for safety. Although this trial marks the first time NEOK001 is tested in humans, early data from lab and animal studies are encouraging. The treatment targets specific proteins in cancer cells, allowing it to attack the cancer effectively while reducing side effects. However, since this is an early-stage trial, researchers are still studying all potential risks.¹²³⁴⁵

NEOK001 is unique because it targets cancer cells in a novel way, potentially offering a new mechanism of action compared to existing treatments like chemotherapy and radiation, which primarily aim to kill fast-dividing cells indiscriminately. This selective targeting could mean fewer side effects and better outcomes for patients. Researchers are excited about NEOK001 as it represents a promising shift towards more personalized and precise cancer therapies.

Research has shown that NEOK001 is a promising new treatment for certain types of cancer. This drug combines an antibody with a cancer-fighting agent, targeting two proteins, B7-H3 and ROR1, commonly found on cancer cells. In animal studies, NEOK001 stopped tumor growth in 81% of cases and caused tumors to shrink in 54% of cases. These results suggest that NEOK001 could effectively target cancer cells in humans and potentially reduce the chance of treatment resistance. This trial will include two experimental arms: a Dose Escalation arm and an Expansion arm, both evaluating the effectiveness of NEOK001 in treating solid tumors in people.³⁴⁵⁶⁷